CTD Holdings’ Senior VP for Medical Affairs Appointed to Committee of the National Academies of Sciences, Engineering, and Medicine

ALACHUA, Fla., Jan. 08, 2019 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that Sharon H. Hrynkow, PhD., has been appointed to a three-year term on the Committee overseeing the Division on Earth and Life Studies (DELS), one of the seven main programmatic units of the National Academies of Sciences, Engineering, and Medicine. Through the efforts of its 11 boards, DELS carries out the Academies’ mission to provide nonpartisan, objective advice to US leaders and decision makers. Activities in DELS cover a wide range of critical issues related to agriculture, management of water and other natural resources; earth sciences; life sciences; chemical sciences and engineering; atmospheric/climate, ocean, and polar sciences; environmental health and toxicology studies; nuclear and radiation science and technology; and animal research.  The announcement was made by CTD’s CEO and Chairman, N. Scott Fine, who said, “Dr. Hrynkow brings intellect, passion and wisdom to all that she does. CTD and its Board of Directors are justifiably proud that she has been appointed to this prestigious Committee.”

The DELS Committee is a group of senior executives and leaders from a range of sectors who oversee the management, operations, and strategic planning of the division. DELS Committee members are big picture thinkers who work together to provide intellectual and strategic leadership for DELS programs. Committee members represent a diversity of expertise and experience, including a mix of academic, industry, governmental (federal and state), and nongovernmental (e.g., foundation) perspectives. 

“I am deeply honored by this appointment and am looking forward to drawing on leadership experiences gained across public, private and non-profit sectors to contribute to the critical work of DELS and to the Academies,” said Dr. Hrynkow.

About the National Academies of Sciences, Engineering, and Medicine:
The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide independent, objective analysis and advice to the nation to solve complex problems and inform public policy decisions related to science, technology, and medicine.  The National Academies operate under an 1863 congressional charter to the National Academy of Sciences, signed by President Lincoln.  For more information, visit http://nationalacademies.org. 

About CTD Holdings:
CTD Holdings, Inc. is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The company’s Trappsol(R) Cyclo(TM), an orphan drug designated product in the United States and Europe, is used to treat Niemann-Pick Disease Type C, a rare and fatal genetic disease, on a compassionate use basis as well as in two ongoing formal clinical trials (Clinical Trials.gov NCT02939547 and NCT02912793). Additional indications for the active ingredient in Trappsol(R) Cyclo(TM) are in development. For additional information, visit the company’s website: www.ctd-holdings.com

Safe Harbor Statement:
This press release contains “forward-looking statements” about the company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company’s future performance include the company’s ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company’s biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company’s filings with the Securities and Exchange Commission, including, but not limited to, the company’s reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

Investor/Media Contact: 
Sitrick and Company 

Wendy Tanaka 
(415) 369-8447 
wtanaka@sitrick.com 

Thomas Mulligan 
(212) 573-6100, Ext. 395 
tmulligan@sitrick.com